Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Janux Therapeutics Inc JANX

Healthcare Biotechnology
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr... see more

Recent & Breaking News (NDAQ:JANX)

Janux Therapeutics Announces Proposed Public Offering

Business Wire 1 day ago

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Business Wire 2 days ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Business Wire 9 days ago

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Business Wire November 6, 2024

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Business Wire August 7, 2024

Janux Therapeutics Announces Updates to Board of Directors

Business Wire July 22, 2024

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Business Wire May 7, 2024

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Business Wire March 8, 2024

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Business Wire February 29, 2024

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Business Wire February 27, 2024

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Business Wire February 26, 2024

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

Business Wire February 20, 2024

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

Business Wire January 8, 2024

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Business Wire November 7, 2023

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Business Wire August 8, 2023

Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Business Wire July 17, 2023

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

Business Wire July 17, 2023

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

Business Wire June 5, 2023

Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Business Wire May 9, 2023

Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences

Business Wire April 24, 2023